Cafelkibart’s entry into phase 3 is of note to Coherus.
ApexOnco Front Page
Recent articles
The company is starting four new pivotal trials this year.
A phase 1 study of OKI-219 reads out imminently.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
Bristol will test the bispecific in two new lung indications.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
The company takes a PD-L1 x VEGF asset into phase 3.
